XML 522 R122.htm IDEA: XBRL DOCUMENT v3.24.0.1
Capital and funding - Summary of Combined Financial Information in Relation to HUL (Details) - EUR (€)
€ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Disclosure of classes of share capital [line items]      
Non-current assets € 57,364 € 58,664  
Current assets 17,902 19,157  
Current liabilities (23,507) (25,427)  
Non-current liabilities (30,995) (30,693)  
Turnover 59,604 60,073 € 52,444
Profit after tax 7,140 8,269 6,621
Total comprehensive income 5,114 8,355 9,977
Equity at beginning of period (21,701) (19,746) (17,655)
Other comprehensive income 2,026 (86)  
Other movements in equity 2 136 [1] (154) [2]
Equity at end of period (20,764) (21,701) (19,746)
Non-controlling interests      
Disclosure of classes of share capital [line items]      
Profit after tax 653 627 572
Total comprehensive income 524 507 749
Equity at beginning of period (2,680) (2,639) (2,389)
Other movements in equity 21 (107) [1] (7) [2]
Equity at end of period (2,662) (2,680) (2,639)
Subsidiaries with material non-controlling interests | Hindustan Unilever Limited      
Disclosure of classes of share capital [line items]      
Non-current assets 6,221 6,354  
Current assets 2,004 1,604  
Current liabilities (1,315) (1,258)  
Non-current liabilities (1,531) (1,152)  
Turnover 6,636 6,828  
Profit after tax 1,147 1,190  
Total comprehensive income 937 940  
Net increase/(decrease) in cash and cash-equivalents (22) 95  
Subsidiaries with material non-controlling interests | Hindustan Unilever Limited | Non-controlling interests      
Disclosure of classes of share capital [line items]      
Profit after tax 437 454  
Equity at beginning of period (2,115) (2,146)  
Other comprehensive income (1) (3)  
Dividend paid to the non-controlling interest 405 395  
Currency translation 80 97  
Other movements in equity 20 (4)  
Equity at end of period € (2,048) € (2,115) € (2,146)
[1] Includes the following items related to the acquisition of Nutrafol: €(269) million non-controlling interest purchase option in other reserves and €99 million non-controlling interest recognised on acquisition.
[2] Includes a hyperinflation adjustment of €280 million and €82 million related to the Welly acquisition.